	2012 Mar 31	2013 Sep 30	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2012 Mar 31	2013 Sep 30	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	18M AR	18M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	1,874	1,948	1,747	873	797	683	600	484	450	560	666	819	922	1,232	1,364
Cost of Operating Revenue	1,152	1,404	1,252	546	535	484	420	321	337	401	513	595	663	992	995
Gross Profit	722	544	495	327	262	199	180	163	113	159	153	225	258	240	369
Gross Margin	38.5	27.9	28.3	37.5	32.9	29.2	30.1	33.6	25.0	28.4	22.9	27.4	28.0	19.5	27.0
Total Operating Expenses	1,585	2,079	1,754	848	945	801	748	574	509	593	637	742	839	1,223	1,376
Operating Profit	288	-132	-7	26	-149	-118	-148	-90	-59	-34	29	78	83	9	-12
Operating Margin	15.4	-6.8	-0.4	2.9	-18.7	-17.2	-24.7	-18.6	-13.1	-6.1	4.4	9.5	9.0	0.7	-0.9
Financing Income/(Expense) - Net	-180	-483	-513	-294	-336	-302	0	-4	-51	-32	-26	7	9	15	-8
Profit before Taxes	75	-573	-389	-296	-544	-399	69	-70	-95	-57	55	92	96	10	-1
Income Taxes	-22	-13	-191	-17	-48	-46	-	-	-	-	-	-3	0	0	0
Profit after Tax	97	-558	-197	-279	-495	-353	69	-131	-117	-2	46	92	100	10	-2
PAT Margin	5.2	-28.7	-11.3	-32.0	-62.2	-51.7	11.6	-27.1	-25.9	-0.3	7.0	11.2	10.8	0.8	-0.1
EPS - Basic - ex Extraordinary Items	3,016.18	-17,264.05	-5,858.82	-6,990.06	-12,138.10	-8,642.81	1,700.49	-17.07	-23.34	-14.80	13.01	19.06	19.65	1.66	-0.88
EPS - Diluted - ex Extraordinary Items	2,980.05	-17,264.05	-5,858.82	-6,990.06	-12,138.10	-8,642.81	1,700.49	-17.07	-23.34	-14.80	13.01	19.06	19.65	1.66	-0.88
EBIT	288	-132	-7	26	-149	-118	-148	-90	-59	-34	29	78	83	9	-12
EBITDA	442	120	317	171	-8	16	-18	36	57	53	84	111	117	52	33
EBITDA Margin	23.6	6.2	18.2	19.6	-1.0	2.3	-3.0	7.5	12.7	9.5	12.6	13.5	12.7	4.2	2.4

Balance Sheet

Abridged

Understanding Balance Sheet

Orchid Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Sep 30	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	C 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	R 2012 Mar 31	2013 Sep 30	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	C 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	1,253	1,101	1,278	973	675	679	767	569	550	450	501	791	807	929
Long-Term Investments	1	1	1	30	24	21	17	2	4	50	51	52	54	74
Property Plant & Equipment - Net	2,248	2,776	1,931	1,778	1,650	1,526	1,404	859	678	593	619	636	696	1,032
Total Non-Current Assets	2,685	3,550	2,783	2,786	2,580	2,446	2,310	891	687	661	724	763	880	1,329
Total Assets	3,938	4,651	4,061	3,759	3,256	3,125	3,077	1,460	1,237	1,111	1,225	1,554	1,688	2,258
Total Current Liabilities	1,551	3,206	1,123	1,299	1,510	2,013	2,346	175	142	241	372	260	286	491
Long Term Debt	1,074	902	2,494	2,378	2,157	1,894	1,425	504	427	208	149	121	132	189
Total Non-Current Liabilities	1,252	1,064	2,609	2,483	2,212	1,905	1,436	519	442	222	165	124	135	203
Total Liabilities	2,803	4,270	3,732	3,782	3,722	3,917	3,781	694	584	463	537	384	421	694
Total Shareholders' Equity	1,132	380	329	-24	-467	-792	-704	766	653	647	689	1,169	1,267	1,564
Minority Interest	3	1	-	-	-	-	-	-	-	-	-	-	-	-
Total Equity	1,135	381	329	-24	-467	-792	-704	766	653	647	689	1,169	1,267	1,564
Total Liabilities & Equity	3,938	4,651	4,061	3,759	3,256	3,125	3,077	1,460	1,237	1,111	1,225	1,554	1,688	2,258

Cash Flow

Abridged

Understanding Cash Flow Statement

Orchid Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Sep 30	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	R 2012 Mar 31	2013 Sep 30	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	18M AR	18M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	135	-265	150	-61	-395	55	137	43	21	90	66	129	143	57
Working Capital - Increase/(Decrease)	357	79	-669	7	449	-38	-110	62	-37	60	-79	-8	-109	71
Net CF from Operating Activities	492	-185	-520	-54	54	17	27	105	-16	150	-13	122	35	128
Capital Expenditures - Net	293	1,039	82	1	9	6	7	4	0	-145	26	65	150	381
Net CF from Investing Activities	-293	-986	1,334	-1	-191	-40	31	143	67	112	-32	-324	-46	-289
Dividends Paid - Cash - Total	25	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock - Issuance/(Retirement) - Net	-	0	74	18	-	-	-	40	-	-	-	392	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	614	1,018	-521	-40	-103	38	-	-290	-125	-185	63	-209	28	147
Net Cash Flow from Financing Activities	-235	1,018	-447	-22	-103	38	-	-250	-125	-185	63	183	28	147
Free Cash Flow to Equity	813	-207	-1,123	-95	-58	48	20	-190	-141	110	24	-152	-87	-106
Free Operating CF net dividend	173	-1,301	-603	-55	45	11	20	100	-16	135	-98	57	-115	-262
Free Operating CF	198	-1,301	-603	-55	45	11	20	100	-16	135	-98	57	-115	-262

Business Segment Analysis

FY End:

Mar 26

Orchid Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 389.62 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 1,231.89 Cr

Assets

Pharmaceuticals (100.0%)₹ 2,258.43 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 8.55 Cr

Regional Segment Analysis

Orchid Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Orchid Pharma Ltd.

Historical Segment Analysis

Track how Orchid Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Pharmaceuticals	85	65	150	390

Frequently Asked Questions

What is the revenue of Orchid Pharma Ltd.?

The latest trailing twelve month revenue of Orchid Pharma Ltd. is ₹ 942.57 Cr, reflecting a 1-year growth of 10.83% and a 3-year CAGR of 9.50%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Orchid Pharma Ltd.?

The latest trailing twelve month net profit (PAT) of Orchid Pharma Ltd. is ₹ 8.02 Cr, with a 3-year earnings CAGR of -40.93%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Orchid Pharma Ltd.?

The trailing twelve month EBITDA of Orchid Pharma Ltd. is approximately ₹ 6.59 Cr (based on an operating margin of 0.70%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Orchid Pharma Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Orchid Pharma Ltd. is 4.05. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Orchid Pharma Ltd.?

The debt-to-equity ratio of Orchid Pharma Ltd. stands at 0.28. The interest coverage ratio is -0.17x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Orchid Pharma Ltd.?

The estimated book value per share of Orchid Pharma Ltd. is 215.04 (derived from a P/B ratio of 3.83 and market price of ₹ 823.30), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Orchid Pharma Ltd.?

The trailing twelve month operating cash flow of Orchid Pharma Ltd. is ₹ 109.88 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Orchid Pharma Ltd. report consolidated or standalone financials?

Orchid Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.